Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Myositis
•
Dermatomyositis
•
Malignancy
How do you manage dermatomyositis related to underlying malignancy?
Is there a role of immunosuppression or treating underlying malignancy will be enough?
Answer from: at Academic Institution
Treat underlying malignancy with urgency Steroid + IVIG is the best treatment for dermatomyositis with active malignancy.
Sign in or Register to read more
14848
Related Questions
How long can you treat dermatomyositis with IVIG?
Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?
How will you sequence therapies in dermatomyositis given the results of the ProDERM trial?
How do you go about switching from one DMARD to another In patients with dermatomyositis that remains active?
In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?
How do you approach weakly positive PL-7 antibody in a patient who initially presented with muscle weakness, rhabdomyolysis and non specific muscular edema on MRI that resolved with IV fluids?
What would be your approach to a patient with Scleroderma/Myositis overlap syndrome (+anti-Ku) and active inflammatory eye disease despite high dose mycophenolate?
Do you use MTX along with Rituximab in patients with early NSIP on HRCT in patient with active RA and polymyositis (PL7+)?
Is the efficacy and dose same for subcutaneous vs intravenous IVIGs being used for dermatomyositis?
When do you consider the use of JAK inhibitors for cutaneous manifestations of myositis?